Structure of Complement Component C2a: Implications for Convertase Formation and Substrate Binding

Structure

Volumn 14, Issue 10, 2006, Pages 1587-1597

  Milder, Fin J ^a   Raaijmakers, Hans C A ^a   Vandeputte, Mitja D A A ^a   Schouten, Arie ^a   Huizinga, Eric G ^a   Romijn, Roland A ^b   Hemrika, Wieger ^b   Roos, Anja ^c   Daha, Mohamed R ^c   Gros, Piet ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

MOLIMMUNO

Indexed keywords

COMPLEMENT COMPONENT C2; COMPLEMENT COMPONENT C2A; CONVERTASE; ENZYME; SERINE PROTEINASE; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ALPHA HELIX; AMINO TERMINAL SEQUENCE; ARTICLE; BINDING AFFINITY; CATALYSIS; CONTROLLED STUDY; CRYSTAL STRUCTURE; EMBRYO; ENZYME ACTIVATION; ENZYME BINDING; ENZYME SPECIFICITY; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN STRUCTURE; STRUCTURE ANALYSIS;

AMINO ACIDS; CATALYTIC DOMAIN; COMPLEMENT ACTIVATION; COMPLEMENT C2A; HUMANS; LIGANDS; MODELS, MOLECULAR; MUTATION; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; SUBSTRATE SPECIFICITY;

EID: 33749265480     PISSN: 09692126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.str.2006.08.008     Document Type: Article

References (39)

1. Barash S., Wang W., and Shi Y. Human secretory signal peptide description by hidden Markov model and generation of a strong artificial signal peptide for secreted protein expression. Biochem. Biophys. Res. Commun. 294 (2002) 835-842
2. Bentley D.R. Primary structure of human complement component C2. Homology to two unrelated protein families. Biochem. J. 239 (1986) 339-345
3. Bhattacharya A.A., Lupher Jr. M.L., Staunton D.E., and Liddington R.C. Crystal structure of the A domain from complement factor B reveals an integrin-like open conformation. Structure 12 (2004) 371-378
4. Bode W. The transition of bovine trypsinogen to a trypsin-like state upon strong ligand binding. II. The binding of the pancreatic trypsin inhibitor and of isoleucine-valine and of sequentially related peptides to trypsinogen and to p-guanidinobenzoate-trypsinogen. J. Mol. Biol. 127 (1979) 357-374
5. Brunger A.T., Adams P.D., Clore G.M., DeLano W.L., Gros P., Grosse-Kunstleve R.W., Jiang J.S., Kuszewski J., Nilges M., Pannu N.S., et al. Crystallography & NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr. D Biol. Crystallogr. 54 (1998) 905-921
6. CCP4 (Collaborative Computational Project, Number 4). The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 50 (1994) 760-763
7. Crump M.P., Ceska T.A., Spyracopoulos L., Henry A., Archibald S.C., Alexander R., Taylor R.J., Findlow S.C., O'Connell J., Robinson M.K., and Shock A. Structure of an allosteric inhibitor of LFA-1 bound to the I-domain studied by crystallography, NMR, and calorimetry. Biochemistry 43 (2004) 2394-2404
8. Durocher Y., Perret S., and Kamen A. High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res. 30 (2002) E9
9. Emsley J., King S.L., Bergelson J.M., and Liddington R.C. Crystal structure of the I domain from integrin α2β1. J. Biol. Chem. 272 (1997) 28512-28517
10. Emsley J., Knight C.G., Farndale R.W., Barnes M.J., and Liddington R.C. Structural basis of collagen recognition by integrin α2β1. Cell 101 (2000) 47-56
11. Fredslund F., Jenner L., Husted L.B., Nyborg J., Andersen G.R., and Sottrup-Jensen L. The structure of bovine complement component 3 reveals the basis for thioester function. J. Mol. Biol. 361 (2006) 115-127
12. Graham F.L., and van der Eb A.J. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 52 (1973) 456-467
13. Hinshelwood J., and Perkins S.J. Conformational changes during the assembly of factor B from its domains by (1)H NMR spectroscopy and molecular modelling: their relevance to the regulation of factor B activity. J. Mol. Biol. 301 (2000) 1267-1285
14. Horiuchi T., Macon K.J., Engler J.A., and Volanakis J.E. Site-directed mutagenesis of the region around Cys-241 of complement component C2. Evidence for a C4b binding site. J. Immunol. 147 (1991) 584-589
15. Janssen B.J., Huizinga E.G., Raaijmakers H.C., Roos A., Daha M.R., Nilsson-Ekdahl K., Nilsson B., and Gros P. Structures of complement component C3 provide insights into the function and evolution of immunity. Nature 437 (2005) 505-511
16. Jin M., Andricioaei I., and Springer T.A. Conversion between three conformational states of integrin I domains with a C-terminal pull spring studied with molecular dynamics. Structure 12 (2004) 2137-2147
17. Jing H., Xu Y., Carson M., Moore D., Macon K.J., Volanakis J.E., and Narayana S.V. New structural motifs on the chymotrypsin fold and their potential roles in complement factor B. EMBO J. 19 (2000) 164-173
18. Jones T.A., Zou J.Y., Cowan S.W., and Kjeldgaard. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr. A 47 Pt. 2 (1991) 110-119
19. Kallen J., Welzenbach K., Ramage P., Geyl D., Kriwacki R., Legge G., Cottens S., Weitz-Schmidt G., and Hommel U. Structural basis for LFA-1 inhibition upon lovastatin binding to the CD11a I-domain. J. Mol. Biol. 292 (1999) 1-9
20. Kam C.M., McRae B.J., Harper J.W., Niemann M.A., Volanakis J.E., and Powers J.C. Human complement proteins D, C2, and B. Active site mapping with peptide thioester substrates. J. Biol. Chem. 262 (1987) 3444-3451
21. Kerr M.A. The human complement system: assembly of the classical pathway C3 convertase. Biochem. J. 189 (1980) 173-181
22. Kerr M.A., and Parkes C. The effects of iodine and thiol-blocking reagents on complement component C2 and on the assembly of the classical-pathway C3 convertase. Biochem. J. 219 (1984) 391-399
23. Khan A.R., and James M.N. Molecular mechanisms for the conversion of zymogens to active proteolytic enzymes. Protein Sci. 7 (1998) 815-836
24. Leslie A.G. The integration of macromolecular diffraction data. Acta Crystallogr. D Biol. Crystallogr. 62 (2006) 48-57
25. Murshudov G.N., Vagin A.A., and Dodson E.J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 53 (1997) 240-255
26. Palmiter R.D., Behringer R.R., Quaife C.J., Maxwell F., Maxwell I.H., and Brinster R.L. Cell lineage ablation in transgenic mice by cell-specific expression of a toxin gene. Cell 50 (1987) 435-443
27. Pangburn M.K., and Muller-Eberhard H.J. The C3 convertase of the alternative pathway of human complement. Enzymic properties of the bimolecular proteinase. Biochem. J. 235 (1986) 723-730
28. Perona J.J., and Craik C.S. Evolutionary divergence of substrate specificity within the chymotrypsin-like serine protease fold. J. Biol. Chem. 272 (1997) 29987-29990
29. Ponnuraj K., Xu Y., Macon K., Moore D., Volanakis J.E., and Narayana S.V. Structural analysis of engineered Bb fragment of complement factor B: insights into the activation mechanism of the alternative pathway C3-convertase. Mol. Cell 14 (2004) 17-28
30. Rawal N., and Pangburn M.K. Structure/function of C5 convertases of complement. Int. Immunopharmacol. 1 (2001) 415-422
31. Roos A., Nauta A.J., Broers D., Faber-Krol M.C., Trouw L.A., Drijfhout J.W., and Daha M.R. Specific inhibition of the classical complement pathway by C1q-binding peptides. J. Immunol. 167 (2001) 7052-7059
32. Shimaoka M., Xiao T., Liu J.H., Yang Y., Dong Y., Jun C.D., McCormack A., Zhang R., Joachimiak A., Takagi J., et al. Structures of the α L I domain and its complex with ICAM-1 reveal a shape-shifting pathway for integrin regulation. Cell 112 (2003) 99-111
33. Song H.K., and Suh S.W. Kunitz-type soybean trypsin inhibitor revisited: refined structure of its complex with porcine trypsin reveals an insight into the interaction between a homologous inhibitor from Erythrina caffra and tissue-type plasminogen activator. J. Mol. Biol. 275 (1998) 347-363
34. Storoni L.C., McCoy A.J., and Read R.J. Likelihood-enhanced fast rotation functions. Acta Crystallogr. D Biol. Crystallogr. 60 (2004) 432-438
35. Tomana M., Niemann M., Garner C., and Volanakis J.E. Carbohydrate composition of the second, third and fifth components and factors B and D of human complement. Mol. Immunol. 22 (1985) 107-111
36. Walport M.J. Complement. First of two parts. N. Engl. J. Med. 344 (2001) 1058-1066
37. Walport M.J. Complement. Second of two parts. N. Engl. J. Med. 344 (2001) 1140-1144
38. Wattanasin S., Kallen J., Myers S., Guo Q., Sabio M., Ehrhardt C., Albert R., Hommel U., Weckbecker G., Welzenbach K., and Weitz-Schmidt G. 1,4-Diazepane-2,5-diones as novel inhibitors of LFA-1. Bioorg. Med. Chem. Lett. 15 (2005) 1217-1220
39. Winn M.D., Isupov M.N., and Murshudov G.N. Use of TLS parameters to model anisotropic displacements in macromolecular refinement. Acta Crystallogr. D Biol. Crystallogr. 57 (2001) 122-133